Cargando…

Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database

OBJECTIVES: Although several years have passed since biologic disease modifying antirheumatic drugs were introduced to the market, considerable disparities in access still remain. Tumour necrosis factor inhibitors (TNFi) have proven to be highly effective and safe for treating patients with rheumati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stajszczyk, Marcin, Obarska, Izabela, Jeka, Slawomir, Batko, Bogdan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Treatment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423465/ https://www.ncbi.nlm.nih.gov/pubmed/37328194 http://dx.doi.org/10.1136/ard-2022-223696

Ejemplares similares

Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
por: Kucharz, Eugeniusz J., et al.
Publicado: (2018)

Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study
por: Batko, Bogdan, et al.
Publicado: (2017)

Methotrexate treatment for rheumatoid arthritis in Poland: Retrospective analysis of patients in routine clinical practice
por: Świerkot, Jerzy, et al.
Publicado: (2018)

Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients – the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response – results from the multicenter observational ACT-POL study
por: Stajszczyk, Marcin, et al.
Publicado: (2022)

Biosimilars: what do patients need to consider?
por: Skingle, Diana
Publicado: (2015)

Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
por: Lai, Zhihong, et al.
Publicado: (2016)

Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?
por: Toussirot, Eric, et al.
Publicado: (2017)

Pneumococcal vaccination in autoimmune rheumatic diseases
por: Rákóczi, Éva, et al.
Publicado: (2017)

Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy
por: Ghalandari, Nafise, et al.
Publicado: (2022)

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
por: Lindström, Ulf, et al.
Publicado: (2019)

Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews
por: Rodriguez-García, Sebastián Cruz, et al.
Publicado: (2021)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?
por: Strand, Vibeke
Publicado: (2021)

Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis
por: Glintborg, Bente, et al.
Publicado: (2018)

Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis
por: Glintborg, Bente, et al.
Publicado: (2019)

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
por: Krieckaert, Charlotte, et al.
Publicado: (2022)

Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies
por: Reinisch, Walter, et al.
Publicado: (2023)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Their Place in the Hospital Budget
Publicado: (1914)

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
por: van der Togt, Céleste J T, et al.
Publicado: (2023)

Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world
por: Sung, Yoon-Kyoung, et al.
Publicado: (2020)

Real-World Data from a Multi-Center Study: Insights to Psoriatic Arthritis Care
por: Batko, Bogdan, et al.
Publicado: (2021)

Non-pharmacological interventions to promote work participation in people with rheumatic and musculoskeletal diseases: a systematic review and meta-analysis from the EULAR taskforce on healthy and sustainable work participation
por: Butink, Maarten H P, et al.
Publicado: (2023)

Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview
por: Toussirot, Éric, et al.
Publicado: (2016)

Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study
por: Barbulescu, Andrei, et al.
Publicado: (2020)

Effectiveness of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers on total and cardiovascular mortality and morbidity in primary prevention: A nationwide study based on French Health Insurance Data (SNDS)
por: Oger, Emmanuel, et al.
Publicado: (2022)

Biosimilar switching – current state of knowledge
por: Wiland, Piotr, et al.
Publicado: (2018)

Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
por: Simoens, Steven, et al.
Publicado: (2017)

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019
por: García-Goñi, Manuel, et al.
Publicado: (2021)

Incidence and factors associated with prescribing renin‐angiotensin‐system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study
por: Nishiwaki, Hiroki, et al.
Publicado: (2021)

Management of rheumatoid arthritis in Poland – where daily practice might not always meet evidence-based guidelines
por: Batko, Bogdan, et al.
Publicado: (2019)

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
por: Calleja, Miguel Angel, et al.
Publicado: (2023)

Ocular involvement in rheumatic diseases
por: Dankiewicz-Fares, Iwona, et al.
Publicado: (2023)

Development of a Psychologically Enhanced Interactive Online Intervention for Hazardous Drinking
por: Linke, Stuart, et al.
Publicado: (2008)

Intervention against Excessive Alcohol Consumption in Primary Health Care: A Survey of GPs' Attitudes and Practices in England 10 Years On
por: Wilson, Graeme B., et al.
Publicado: (2011)

A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction
por: Parthasarathy, Hari K., et al.
Publicado: (2009)

Twelve-Month Follow-up Results from a Randomized Controlled Trial of a Brief Personalized Feedback Intervention for Problem Drinkers
por: Cunningham, John A., et al.
Publicado: (2010)

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial
por: Düngen, Hans-Dirk, et al.
Publicado: (2011)

Early Treatment for Women with Alcohol Addiction (EWA) Reduces Mortality: A Randomized Controlled Trial with Long-Term Register Follow-up
por: Gjestad, Rolf, et al.
Publicado: (2011)

Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial
por: Cohen-Solal, Alain, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_iig9pbim13q55c6thvt1rq76j7